C.F.R. homeSearch C.F.R.
C.F.R.Title 21Chapter I—Food and Drug Administration, Department of Health and Human ServicesSubchapter C—Drugs: GeneralPart 211—Current Good Manufacturing Practice for Finished PharmaceuticalsSubpart I—Laboratory Controls

21 C.F.R. § 211.165 (2026)

Testing and release for distribution

Edition and currency
eCFR text as of Sept. 29, 2026. The text is the edition Syfert holds; for a past event, check the version in force on that date.
Other sources
CURRENTeCFR text as of Sept. 29, 2026 ACTIVE · 3 IN 5Y cited 1993–2025 10citing cases
At a glance

Courts have cited this section in 10 opinions since 1993, 3 of them in the last five years. The most litigated part is subsection (a) (1 case).

(a) For each batch of drug product, there shall be appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release. Where sterility and/or pyrogen testing are conducted on specific batches of shortlived radiopharmaceuticals, such batches may be released prior to completion of sterility and/or pyrogen testing, provided such testing is completed as soon as possible.

(b) There shall be appropriate laboratory testing, as necessary, of each batch of drug product required to be free of objectionable microorganisms.

(c) Any sampling and testing plans shall be described in written procedures that shall include the method of sampling and the number of units per batch to be tested; such written procedure shall be followed.

(d) Acceptance criteria for the sampling and testing conducted by the quality control unit shall be adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release. The statistical quality control criteria shall include appropriate acceptance levels and/or appropriate rejection levels.

(e) The accuracy, sensitivity, specificity, and reproducibility of test methods employed by the firm shall be established and documented. Such validation and documentation may be accomplished in accordance with § 211.194(a)(2).

(f) Drug products failing to meet established standards or specifications and any other relevant quality control criteria shall be rejected. Reprocessing may be performed. Prior to acceptance and use, reprocessed material must meet appropriate standards, specifications, and any other relevant criteria.

The 10 cases that cite 21 C.F.R. § 211.165 most heavily, weighted by court and treatment. RelevanceNewestTreatment
1
GREENMomenta Pharm., Inc. v. Amphastar Pharm., Inc., 686 F.3d 1348 (Fed. Cir. 2012).
cites § 211.165 7×cited by 42 cases
Where it cites § 211.165
“See 21 C.F.R. § 211.165 (a). This test must be done according to the patented methods de- scribed in an official compendium, in this case the United States Pharmacopeia (USP).”
The case’s holding
The statutory safe harbor covers post-approval testing reasonably related to developing and submitting information to the FDA rather than being limited to pre-approval activities.
Later courts cite it for
“an unduly narrow interpretation” · 4 citing courts
2
GREENMedicines Co. v. Mylan, Inc., 853 F.3d 1296 (Fed. Cir. 2017).
cites § 211.165 2×cited by 27 cases
Where it cites § 211.165
“1993); 21 C.F.R. § 211.165 (f). Between 2001 and 2005, Medicines and its contract manufacturer, Ben Venue Laboratories (“BVL”), produced and sold numerous batches of compounded bivalirudin having Asp9 levels of less than 1.”
The case’s holding
A claim term is construed according to the specific conditions described in the specification when the specification defines the term as achieving a particular result.
Later courts cite it for
“although there is no per se rule against negative constructions,” · 2 citing courts
3
GREENMomenta Pharm., Inc. v. Teva Pharm. USA Inc., 809 F.3d 610 (Fed. Cir. 2015).
cites § 211.165 2×cited by 18 cases
Later courts cite it for
“abtox stated 'as long as an activity is reasonably related to obtaining fda approval.” · 2 citing courts
4
GREENUnited States v. Barr Labs., Inc., 812 F. Supp. 458 (D.N.J. 1993).
cites § 211.165 2×subsections: (a) 2×cited by 13 cases
Where it cites § 211.165
“21 C.F.R. 211.165(a). And section 211.-165(f) specifies: Drug products failing to meet established standards or specifications and any other relevant quality control criteria shall be rejected.”
5
GREENHill Dermaceuticals, Inc. v. U.S. Food & Drug Admin., 826 F. Supp. 2d 252 (D.D.C. 2011).
cites § 211.165 1×cited by 4 cases
Summary
No passage or summary on file for this case yet.
6
NO FLAGPar Pharm., Inc. v. Eagle Pharm., Inc., No. 1:18-cv-00823 (D. Del. Aug. 31, 2021).
cites § 211.165 2×cited by 0 casesunknown
Where it cites § 211.165
“The parties agree, and I find, that the FDA’s definition of “release specification” is set forth in 21 C.F.R. § 211.165 . Section 211.165(a) provides that “Tflor each batch of [a] drug product, there shall be appropriate laboratory determination of satisfactory conformance to…”
7
NO FLAGPfizer Inc. v. State of Texas & Tarik Ahmed, No. 15-25-00021-CV (Tex. App.—15th Dist. Feb. 28, 2025).
cites § 211.165 2×cited by 0 cases
Summary
No passage or summary on file for this case yet.
8
NO FLAGDaugherty v. Padagis Israel Pharm. Ltd., No. 3:24-cv-02066 (N.D. Cal. Aug. 6, 2025).
cites § 211.165 2×cited by 0 casesunknown
Where it cites § 211.165
“FAC ¶ 68(i); see 21 C.F.R. § 211.165 (a). This cGMP regulation provides: 4 For each batch of drug product, there shall be appropriate 5 laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and 6 strength of…”
9
NO FLAGIn re MDL 2700 Genentech, No. 19-5035 (10th Cir. May 29, 2020).
cites § 211.165 1×cited by 0 cases
Where it cites § 211.165
“” 21 C.F.R. § 211.165 (a). “Drug products failing to meet established standards or specifications and any other relevant quality control criteria shall be rejected.”
10
NO FLAGIn re Genentech, Inc., 367 F. Supp. 3d 1274 (N.D. Okla. 2019).
cites § 211.165 1×cited by 0 cases
Where it cites § 211.165
“21 C.F.R. § 211.165 (a). It also includes data from studies showing that the product meets prescribed requirements for safety, purity and potency; a full description of manufacturing methods; data establishing product stability; samples of the product, labeling, and containers;…”

The flag is Syfertize’s treatment of the citing case itself, not of the statute. “Where it cites” is the passage in the opinion; the holding is a summary of the whole case and may concern another point. Annotations are extracted automatically from the opinions in the Syfert caselaw corpus.

Citing cases by year
199320092025

One bar per year. Tallest: 2 cases in 2025. These are opinions in the Syfert collection, which holds more of some courts’ recent opinions than their older ones, so a rise can reflect what the collection holds and not more litigation.

By court
Fed. Cir.310th Cir.1N.D. Cal.1D.D.C.1D. Del.1D.N.J.1N.D. Okla.1Tex. App.1
By subsection
(a)1 case
United States v. Barr Labs., Inc., 812 F. Supp. 458 (D.N.J. 1993).“21 C.F.R. 211.165(a). And section 211.-165(f) specifies: Drug products failing to meet established standards or specifications and any other relevant quality control criteria shall be rejected.”
Enactment and amendments

Syfert holds no separate history line for this section. Where this code prints a source or history note, it appears with the text, usually at the end.

Versions

Edition shown: eCFR text as of Sept. 29, 2026. Syfert holds no earlier or later version of this section.

C.F.R. Home  |  Search C.F.R.  |  Search cases for this section  |  syfert.com